European Commission conditionally approves Bayer & #8217;s proposed acquisition of Monsanto
Closing of transaction planned for the second quarter of 2018 (Source: Bayer Company News)
Source: Bayer Company News - March 21, 2018 Category: Pharmaceuticals Source Type: news
Bayer and Ginkgo Bioworks unveil joint venture, Joyn Bio, and establish operations in Boston and West Sacramento
Joyn Bio’s initial efforts focus on nitrogen fixation to enhance sustainability in agriculture / Researchers will broadly explore application of beneficial microbes to plants for next generation solutions to agriculture’s biggest challenges / Dr. Mike Miille appointed as CEO (Source: Bayer Company News)
Source: Bayer Company News - March 20, 2018 Category: Pharmaceuticals Source Type: news
Bayer in exclusive talks with BASF on the sale of vegetable seeds business
(Source: Bayer Company News)
Source: Bayer Company News - March 7, 2018 Category: Pharmaceuticals Source Type: news
Bayer: business at prior-year level & #8211; on track with strategy
Group sales increased by 1.5 percent (Fx& portfolio adj.) to 35.015 billion euros / Another record year for Pharmaceuticals / Weak business development at Consumer Health / Crop Science business down against prior year due to situation in Brazil– measures taking effect / EBITDA before special items level year on year at 9.288 billion euros / Net income raised by 61.9 percent to 7.336 billion euros / Core earnings per share increased by 1.0 percent to 6.74 euros / Covestro deconsolidated– additional cash inflows of 4.7 billion euros / Monsanto acquisition expected to close in second quarter of 2018 / Group outlo...
Source: Bayer Company News - February 28, 2018 Category: Pharmaceuticals Source Type: news
Bayer proposes increased dividend for 2017 of 2.80 euros per share
Payment per share rises 3.7 percent (Source: Bayer Company News)
Source: Bayer Company News - February 27, 2018 Category: Pharmaceuticals Source Type: news
Bayer receives first approval for Eylea ® in China (for specialized target groups only)
Eylea is the first anti-VEGF drug approved in China for the treatment of visual impairment due to diabetic macular edema in patients with DME (Source: Bayer Company News)
Source: Bayer Company News - February 13, 2018 Category: Pharmaceuticals Source Type: news
New data for aflibercept show prolonged injection intervals (for specialized target groups only)
Data from ALTAIR study demonstrate injection appointments at an interval of 12 weeks or more / New data submitted to EMA to update the current product information (Source: Bayer Company News)
Source: Bayer Company News - February 12, 2018 Category: Pharmaceuticals Source Type: news
FDA report reaffirms safety profile and effectiveness of Bayer ’s Xarelto® in routine clinical practice (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - January 16, 2018 Category: Pharmaceuticals Source Type: news
FDA report reaffirms safety profile and effectiveness of Bayer & #8217;s Xarelto ® in routine clinical practice (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - January 16, 2018 Category: Pharmaceuticals Source Type: news
Bayer sells 10.4 percent stake in Covestro
Placement volume considerably higher than planned (Source: Bayer Company News)
Source: Bayer Company News - January 11, 2018 Category: Pharmaceuticals Source Type: news
Bayer further reduces holding in Covestro
Accelerated bookbuilding process started (Source: Bayer Company News)
Source: Bayer Company News - January 10, 2018 Category: Pharmaceuticals Source Type: news
Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers (for specialized target groups only)
Completion of NDA submission expected in early 2018 (Source: Bayer Company News)
Source: Bayer Company News - December 20, 2017 Category: Pharmaceuticals Source Type: news
Bayer receives approval in China for Stivarga ® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)
Approval based on data from the Phase III RESORCE study where Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - December 13, 2017 Category: Pharmaceuticals Source Type: news
